Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
BeiGene, Ltd. (BGNE) Insider Trading Activity
Healthcare • Biotechnology • 10,000 employees
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
Total Value
-$466,280,802.37
Total Shares
-495,909
Average Trade Value
-$10,136,539.18
Most Active Insider
Baker Bros. Advisors Lp
Total Activity: $384,735,063
Largest Single Transaction
$174,713,760
by Baker Bros. Advisors Lp on Feb 28, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
| Feb 28, 2025 | 60,851 | $15,821,260 | 730,642 (-8.3%) | Sale | ||
| Feb 28, 2025 | 671,976 | $174,713,760 | 8,068,411 (-8.3%) | Sale | ||
|
Director
|
Jan 7, 2025 | 4,260 | $755,810 | 6,939 (-61.4%) | Sale | |
|
Director
|
Jan 7, 2025 | 11,310 | $1,998,090 | 11,199 (-101.0%) | Sale | |
|
Director
|
Jan 7, 2025 | 1,301 | $233,119 | 0 | Sale | |
|
Director
|
Jan 7, 2025 | 41,760 | $271,440 | 41,760 (+100.0%) | Exercise/Conversion | |
|
Director
|
Jan 7, 2025 | 19,251 | $3,377,728 | 22,509 (-85.5%) | Sale | |
|
Director
|
Jan 7, 2025 | 5,638 | $1,005,766 | 1,301 (-433.4%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Dec 14, 2024 | 1,300,000 | $650,000 | 2,978,833 (+43.6%) | Exercise/Conversion | |
| Dec 9, 2024 | 916,964 | $171,013,786 | 8,740,387 (-10.5%) | Sale | ||
| Dec 9, 2024 | 33,943 | $7,060,609 | 9,657,351 (-0.4%) | Sale | ||
| Dec 9, 2024 | 83,036 | $15,486,214 | 791,493 (-10.5%) | Sale | ||
| Dec 9, 2024 | 3,074 | $639,434 | 874,529 (-0.4%) | Sale | ||
|
President, COO Gm China
Officer
|
Dec 6, 2024 | 0 | $62,399,999 | 0 | Sale | |
|
Director
|
Nov 26, 2024 | 600 | $113,418 | 5,083 (-11.8%) | Sale | |
|
Director
|
Nov 26, 2024 | 1,475 | $280,703 | 3,608 (-40.9%) | Sale | |
|
Director
|
Nov 26, 2024 | 2,725 | $521,117 | 883 (-308.6%) | Sale | |
|
Director
|
Nov 26, 2024 | 883 | $169,436 | 0 | Sale | |
|
Director
|
Nov 26, 2024 | 12,293 | $2,350,704 | 7,388 (-166.4%) | Sale | |
|
Director
|
Nov 26, 2024 | 38,461 | $249,997 | 40,468 (+95.0%) | Exercise/Conversion | |
|
Director
|
Nov 26, 2024 | 5,875 | $1,104,391 | 29,868 (-19.7%) | Sale | |
|
Director
|
Nov 26, 2024 | 4,425 | $828,172 | 36,043 (-12.3%) | Sale | |
|
Director
|
Nov 26, 2024 | 300 | $56,282 | 35,743 (-0.8%) | Sale | |
|
Director
|
Nov 26, 2024 | 400 | $75,419 | 29,468 (-1.4%) | Sale | |
|
Director
|
Nov 26, 2024 | 2,700 | $510,748 | 26,768 (-10.1%) | Sale | |
|
Director
|
Nov 26, 2024 | 200 | $37,952 | 26,568 (-0.8%) | Sale | |
|
Director
|
Nov 26, 2024 | 6,187 | $1,177,517 | 20,381 (-30.4%) | Sale | |
|
Director
|
Nov 26, 2024 | 700 | $133,732 | 19,681 (-3.6%) | Sale | |
|
Director
|
Nov 26, 2024 | 407 | $78,066 | 6,981 (-5.8%) | Sale | |
|
Director
|
Nov 26, 2024 | 6,981 | $1,340,087 | 0 | Sale | |
|
Director
|
Nov 26, 2024 | 1,014 | $189,765 | 6,869 (-14.8%) | Sale | |
|
Director
|
Nov 26, 2024 | 1,186 | $223,060 | 5,683 (-20.9%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 1,747 | $401,897 | 2,863 (-61.0%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 229 | $52,909 | 2,634 (-8.7%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 1,452 | $343,209 | 0 | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 2,059 | $484,715 | 1,452 (-141.8%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 1,272 | $299,445 | 896 (-142.0%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 428 | $100,269 | 2,168 (-19.7%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 371 | $85,718 | 4,267 (-8.7%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 38 | $8,854 | 2,596 (-1.5%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 1,565 | $358,770 | 4,610 (-33.9%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 62 | $14,446 | 4,205 (-1.5%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 2,535 | $581,139 | 7,465 (-34.0%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 896 | $211,787 | 0 | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 694 | $162,585 | 3,511 (-19.8%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Oct 8, 2024 | 2,827 | $650,350 | 4,638 (-61.0%) | Sale |